title: Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial.
abstract: OBJECTIVE
  To investigate the efficacy and safety of topiramate versus placebo as adjunctive therapy for the outpatient management of bipolar I disorder.
  
  
  METHODS
  In this 12-week, randomized, double-blind, placebo-controlled trial, adults with bipolar I disorder (DSM-IV criteria) experiencing a manic or mixed episode with a Young Mania Rating Scale (YMRS) score of >or= 18 while taking therapeutic levels of valproate or lithium received adjunctive topiramate or placebo. Topiramate was titrated from 25 to 400 mg/day over 8 weeks and was continued for 4 additional weeks. The study was conducted from October 2001 through October 2003. The primary outcome measure was the change in YMRS score from baseline to last study visit during the double-blind phase.
  
  
  RESULTS
  The mean +/- SD change in YMRS score from baseline was -10.1 +/- 8.7 (-40.1%) in the topiramate group (N = 143) and -9.6 +/- 8.2 (-40.2%) in the placebo group (N = 144, p = .797). Greater than 50% reduction in YMRS was achieved by 39% of the topiramate group and 38% of the placebo group (p = .914). No significant treatment differences were observed for secondary efficacy measures. Compared with adjunctive placebo, adjunctive topiramate did not worsen mania or induce depression. Paresthesia, diarrhea, and anorexia were more common in the topiramate group. The topiramate group achieved greater reductions than the placebo group in body weight (-2.5 vs. 0.2 kg, p < .001) and body mass index (-0.84 vs. 0.07 kg/m(2), p < .001).
  
  
  CONCLUSIONS
  In patients treated with lithium or valproate, there was no difference in the reduction of YMRS score in the topiramate and placebo groups. Both groups showed declines of 40%. Topiramate reduced body weight significantly relative to placebo without worsening depressive or manic symptoms.
authors.affiliation: Department of Psychiatry, University of Pittsburgh Medical Center and Mayview State Hospital, Pittsburgh, Pa., USA. chengappakn@upmc.edu
authors.forename: K N
authors.initials: KN
authors.lastname: Roy Chengappa
authors.forename: Lesley K
authors.initials: LK
authors.lastname: Schwarzman
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Hulihan
authors.forename: Jim
authors.initials: J
authors.lastname: Xiang
authors.forename: Norman R
authors.initials: NR
authors.lastname: Rosenthal
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000008:administration & dosage; D001714:Bipolar Disorder / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D018020:Lithium Compounds / Q000008:administration & dosage*; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage; D000077236:Topiramate; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage*
chemical_list: D018692:Antimanic Agents; D018020:Lithium Compounds; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid